Laine Ooi PhD, Dabt
About Laine Ooi PhD, Dabt
Laine Ooi, PhD, Dabt, serves as the Senior Director of Nonclinical Development and Safety Assessment at Arcus Biosciences, where she specializes in nonclinical safety assessment for small molecule and antibody therapies. She has extensive experience in guiding drug development programs from early stages to registration.
Work at Arcus Biosciences
Currently, Laine Ooi serves as the Senior Director of Nonclinical Development and Safety Assessment at Arcus Biosciences. She has held this position since 2024, contributing to the organization's focus on the safety assessment of therapeutic candidates. Prior to this role, she was the Associate Director of Preclinical Development from 2017 to 2020 and the Director of Preclinical Development from 2020 to 2024. Her tenure at Arcus Biosciences has involved guiding drug development programs through various stages, including IND-enabling programs and registration.
Education and Expertise
Laine Ooi earned her PhD in Cancer Biology from the University of Sydney, Australia, where she studied from 2007 to 2010. She also holds a Bachelor of Science with Honours in Biotechnology from Monash University, which she completed from 2002 to 2005. Her academic background supports her expertise in nonclinical safety assessment for both small molecule and antibody therapies, emphasizing her knowledge in preclinical development.
Background
Laine Ooi has extensive experience in the biopharmaceutical industry, with a career spanning various roles focused on drug development and safety assessment. Before her current position, she worked at Thermo Fisher Scientific as a Scientist for three months in 2015, and she held positions at Comparative Biosciences as a Pharmacology/Toxicology Study Director from 2016 to 2017, OSI Pharmaceuticals as a Research Scientist from 2011 to 2012, and Principia Biopharma as a Scientist in Pharmacology from 2013 to 2015.
Achievements
Laine Ooi has guided numerous drug development programs from early stages through to IND-enabling programs and registration. Her work in nonclinical safety assessment has been critical in advancing therapeutic candidates in the biopharmaceutical sector. Her roles across various organizations demonstrate her commitment to ensuring the safety and efficacy of new therapies.